Codexis, Inc.
NMS: CDXSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Codexis, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CDXS Z-Score →About Codexis, Inc.
Healthcare
Biotechnology
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
📊 Fundamental Analysis
Codexis, Inc. demonstrates a profit margin of -62.5%, which is below the sector average, suggesting competitive pressure.
The company recently reported 81.3% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -74.9%, which indicates that capital utilization is currently under pressure.
At a current price of $2.24, CDXS currently sits at the 44th percentile of its 52-week range (Range: $0.96 - $3.87).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$203.55M
Trailing P/E
--
Forward P/E
-10.18
Beta (5Y)
2.08
52W High
$3.87
52W Low
$0.96
Avg Volume
2.37M
Day High
Day Low